

USAID Assistance is scaling up MDR-TB response

Nilufar Rakhmanova MD, MPH

Regional TB Advisor, USAID/CAR



USAID CENTRAL ASIAN REPUBLICS



Outline

Regional Context

USAID support for MDR-TB model

Opportunities/priorities

Donor and technical leadership

- National TB leadership
- WHO TA
- Global Fund Grants:
- Kazakhstan (Round 6, 8)
- Uzbekistan (Round 4, 8)
- Tajikistan (Round 3, 6, 8)
- Turkmenistan (Round 9)
- Kyrgyzstan (Round 2, 6)
- USAID
- KFW

Key USG developments

- 2008 Lantos -Hyde Reauthorization Act that supports activities under WHO Global Plant to Stop TB.
- 2009 President Obama announced Global Health Initiative, 6 year \$ 63 billion with PEPFAR as a cornerstone
- The global targets by 2014:
 - 1. Reduce TB prevalence by 50% (1990 baseline)
 - 2. Treat 2,6 million new SS+ TB cases
 - 3. Treat 57,200 MDRTB cases



USAID support 2003-2008

UAB/GORGAS of MDR-TB case management in Almaty city:

- Developed MDR-TB case management protocols;
- Strengthened laboratory capacity;
- Improved drug management system;
- Enhanced Infection control measures;
- Developed MDR-TB information system;
- TA in approval of GLC application for 380 MDR TB patients.



UAB/GORGAS model of MDR-TB case management

Intervention	Change
Standards and monitoring	Pre-classification mistakes decreased from 16% in 2005 to 5.7% in 2008
11 protocols	Basis for national guidelines
Compliance to protocol through audit	77.1% in 2006 to 87% in 2008
Treatment success for SLD	84.4% of MDR TB patients enrolled in 2005



USAID support 2008-present

-			
MDR-TB component	Project	Implementer	Countries
Drug resistance surveys	Division of TB elimination in CDC Atlanta	CDC	Kyrgyzstan, Tajikistan
Infection control	TB CAP	KNCV	CAR
MDR-TB case management and social support	ТВ САР	KNCV	CAR and Eastern Kazakhstan
Social Support and DOT	Social support to MDRTB	IFRC through NRC	Almaty, Kizilorda
TA in MDRTB and MGIT in TX	Project HOPE	2009	CAR
Information system	E-TB Manager	MSH	Uzbekistan



MDRTB case management & social support project 2009-2010 (TBCAP: CAR lead implementer is KNCV)

Regional Summary of best PN

Summary of best PMDT practices

PMDT workshops

Analysis of social support programs

Kazakhstan

MDR TB training capacity in Almaty city


MDR TB case management and social support model expanded to Eastern Kazakhstan (EK) including the prison sector

MDR -TB case management model in Eastern Kazakhstan (EK) TBCAP/KNCV

- Eastern Kazakhstan is 1200 km from North to South and 800 km from East to West
- Semey 310,000 p
- Oskemen 298,200 p
- 150 MDR-TB beds
- 14 penitentiary institutions, 10421 detainees
- On average 700 cases of MDR-TB cases a year

Why Eastern Kazakhstan?


Rate of TB mortality (national average, EKO oblast and EKO prison)



Source: Department of organization and methodology, OTBD and TB statistical overview, Almaty (1999-2008)

Why Eastern Kazakhstan?

Rate of MDRTB in EKO in comparison with the national average)



□ МЛУ ТБ РК □ МЛУ ТБ ВКО

Source: Department of organization and methodology, OTBD and TB statistical overview, Almaty (1999-2008)



Multifaceted approach to combat MDRTB in EKO

- The oblast workplan was developed and approved by EKO health department. (June 2009)
- TOT was conducted at April 2009 and Feb 2010
- The East Kazakhstan Oblast has adapted **13 MDR TB** case management protocols including prison system.
- Established a model of **psycho-socio-economical support** in **EKO** to decrease a default rate among 60 MDRTB patients (since October 2009)



TBCAP/KNCV model of MDR-TB management and social support

Intervention	Impact
13 protocols adapted and approved	The diagnosis and treatment standardized
Established social support team: Social worker+psychologist+nurses+do ctor	60 patients are receiving comprehensive support; all MDR-TB patients are reimbursed or transportation while on treatment in Semey
TOT in MDR-TB case management	National TB Training center strengthened



Social support team


ASIAN REPUBLICS



Meeting with akimat (local government)



Epidemiological trend




Source: Department of organization and methodology, OTBD and TB statistical overview. EKO(12003-2008)



Epidemiological trend

Treatment outcomes among MDR-TB



- □ Cured
- Failure
- Died
- Defaulted



Social support and DOT to MDR-TB patients (IFRC)

- Implemented by IFRC/KRCS
- MDRTB patients in Almaty 338 and Kzylorda 514 (31%)/ 80 of them are covered by project
- Goals:
- Ensuring DOTS plus is completed
- Raising awareness among risk
- Providing psycho-social support

Source: Statistical Review of TB in Kazakhstan of the National TB Centre, 2008

MDR-TB component	Project	Implementer	Countries
Drug resistant surveys	Division of TB elimination in CDC Atlanta	CDC 2009-2011	Kyrgyzstan, Tajikistan
Infection control	TB CAP	KNCV 2010	CAR
MDR-TB case management and social support	TB CAP	KNCV 2010	CAR and Eastern Kazakhstan
Social Support and DOT	Social support to MDRTB	IFRC through NRC 2010	Almaty, Kizilorda
TA in MDRTB and MGIT in TX	Project HOPE	2009	CAR
Information system	E-TB Manager	MSH 2010	Uzbekistan
Comprehensive TB/MDRTB TA	Health Improvement Project, HIP		CAR

Capacity TB/HIV project (2004-2009)

- 4 pilot in 4 countries of CAR:
- Kazakhstan (Almaty), Tajikistan (Dushanbe), Kyrgyzstan (Chuy) and Uzbekistan (Tashkent)
- Technical working groups
- Developed M&E tools
- Supported M&E
- Prikazes in TB/HIV
- Regular meetings to share data
- Trained TB and HIV specialists
- Scale up pilots → GFATM in Kazakhstan & Tajikistan

Health Outreach Project (PSI, AFEW, HOPE, PLWA)

- Target MARPS (PLWA, prisoners, sex workers, IDUs, migrants, MSM)
- Outreach to prevent & detect TB and HIV
- Referral to friendly services (prevention and treatment)
- Training for providers on HIV and TB among pharmacists, STI specialists, narcologists) (+stigma)
- Subgrants to NGO and strengthening capacity of NGOs
- Working with PLA on TB diagnosis, prevention, treatment , adherence to ART, TB treatment
- Survey on behavioral determinant (adherers)

Opportunities/gaps

Opportunities/gaps
Infection prevention and control
Laboratory Quality Assurance
Electronic TB surveillance system
Improving continuum of care
MDRTB case management
Social support model
Increasing community awareness & stigma reduction



Thank you!

DRUG SENSITIVITY TO FIRST LINE DRUGS IN NEWLY DETECTED SS +

	2005	2006	2007	2008
Total examined	832	639	641	293
Sensitive	58.2	43.8	41.6	37.5
Resistant	41.7	54.7	58.3	62.4
MDR	10.5	16.5	26.2	35.8

DRUG SENSITIVITY TO FIRST LINE DRUGS IN RETREATED

	2005	2006	2007	2008
Total examined	605	661	538	412
Sensitive	32.0	20.3	15.0	15.8
Resistant	68.0	79.7	84.9	84.2
MDR	37.5	57.9	65.9	66.9

Source: Oblast TB laboratory, EKO (2005-2009)